Articles By: Energy Bulletin
Two Obamacare Mandates That Dramatically Expand The Internal Revenue Service’s Power
Treasury Dept. Endorses Narrow Interpretation of Obamacare’s Affordable Coverage Provision Avik Roy Contributor Obamacare’s Dark Secret: The Individual Mandate is Too Weak Avik Roy Contributor What’s Democrats’ Plan B If the Individual Mandate Goes Down? Avik Roy Contributor Yet Another Obamacare Foul-Up: Participants in Federally-Run Insurance Exchanges May Be Ineligible for Subsidies Avik Roy Contributor [...]
New App Lets You Boycott Koch Brothers, Monsanto And More By Scanning Your Shopping Cart
Meet The Cathys: Your Guide To The Billionaires Behind Chick-fil-A Clare O’Connor Forbes Staff Want To Boycott Koch Brothers’ Products While Shopping? There’s An App For That Clare O’Connor Forbes Staff SCOTUS Upholds Monsanto Soybean Patent, Postponing Debate Over Self-Replicating Technologies Daniel Fisher Forbes Staff Buycott shows you a product’s corporate family tree while you [...]
Our Limitless Capacity For Self-Deception
I want to share with my readers a recent post and accompanying comment published on CardioExchange. The original post is by Eric Lindley, a cardiology fellow at the University of Utah: Journal X: Not so Subtle Marketing Messages I was the rare resident who thought that conflict of interest issues in medicine were a bit [...]
JC Penney vs. Johnson & Johnson: The Difference Between Words and Actions
Johnson Johnson Unveils New Corporate Branding Campaign Jennifer Rooney Forbes Staff With New Ad, J.C. Penney Plays The Card It Can Only Play Once Will Burns Contributor Ford India Apologizes For Advertisements It Never Ran Kenneth Rapoza Contributor In the past few weeks, three of the top brands in the world have had to launch [...]
Oregon Study: Medicaid ‘Had No Significant Effect’ On Health Outcomes vs. Being Uninsured
Economists Claim Medicaid’s Health Outcomes are Great. Or Do They? Avik Roy Contributor Why Medicaid is a Humanitarian Catastrophe Avik Roy Contributor Opposing Obamacare is No Longer Enough: Toward A New Conservative Health Care Agenda Avik Roy Contributor Florida’s Innovative, Consumer-Driven Replacement for Obamacare’s Medicaid Expansion Avik Roy Contributor Providence Portland Medical Center in Oregon, [...]
What The Pfizer-Merck Diabetes Deal Teaches About Today’s Pharma R&D
Earlier today, Pfizer and Merck announced a new partnership in the area of diabetes drug research. The companies will join forces to develop and commercialize ertugliflozin (PF-04971729), an oral sodium glucose cotransporter (SGLT2) inhibitor for type 2 diabetes which is about to begin phase 3 studies. SGLT2 inhibitors are a new class of antidiabetic drugs, [...]
Lilly And Sanofi CEOs Take Two Very Different R&D Paths In Alzheimer’s Disease
Alzheimer’s Disease (AD) RD might be the most challenging therapeutic area that faces medicine today. It is known that AD is caused by the build-up of proteins into clusters that clog up nerve cells in the brain. These “plaques” break down nerve cells which, in turn, results in a decrease in the ability of these [...]
A Film Producer, A Cancer Doctor, And Their Critics
I just returned from the Cleveland Clinic, one of the world’s most respected medical centers. By a quick check on PubMed, the (young) doctor I met there has about 60 publications to his name, all in well-respected journals. He’s recognized as one of the best in his field, and people come from all over the [...]
Nutritional Supplements Flexing Muscles As Growth Industry
One of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements, or VMS. Producing about $32 billion in revenue for just nutritional supplements alone in 2012, it is projected to double that by topping $60 billion in 2021 according to the Nutritional Business [...]
Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies. The drug generated $266 million in annual sales last year, helping Acorda generate a net profit, excluding a large one-time tax benefit, of $50 million. This morning, Acorda announced in a press [...]
- A 288 g/t Gold Windfall for Eagle Hill May 15, 2013 Financial Press
- Garmatex CEO Identifies Multi-Billion Dollar Opportunity in Global Performance Textile Market May 14, 2013 Financial Press
- Scout Set to Solve Big Oil’s Biggest Problem May 2, 2013 Financial Press
- Garmatex’s Kottinu(TM) keeps Cool-jams’ award-winning innovation at the forefront of sleepwear May 1, 2013 Financial Press
- Solid Resources buoyant on Spain economy April 30, 2013 Financial Press
Featured Articles
- The Real Story Behind INFI, ARIA, GT and BTU May 18, 2013
- The Straight Truth, Investing in GRPN, INTC and PFE May 18, 2013
- The Reason It Trades, What's Moving GDX, DDR, TSLA and AAPL May 18, 2013
- Profitable Trading Secrets Revealed in GILD, NWSA, RF and MTG May 18, 2013
- Year-End Ceremony at Royal Military College Saint-Jean May 18, 2013
